CHRS vs MGNX vs RCUS vs FATE

For growth investors, MacroGenics, Inc.

(MGNX) is the stronger pick with 0. 8% revenue growth year-over-year, versus -84. 2% for Coherus Oncology, Inc. (CHRS). Coherus Oncology, Inc. (CHRS) offers the better valuation at 1. 2x trailing P/E, making it the more compelling value choice. Analysts rate Coherus Oncology, Inc. (CHRS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Arcus Biosciences, Inc.

(RCUS) delivered a total return of -12. 1%, compared to -96. 8% for Fate Therapeutics, Inc. (FATE). Over 10 years, the gap is even starker: RCUS returned +49. 2% versus CHRS's -90. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), MacroGenics, Inc.

(MGNX) is the lower-risk stock at 1. 76β versus Coherus Oncology, Inc. 's 2. 15β — meaning CHRS is approximately 23% more volatile than MGNX relative to the S&P 500. On balance sheet safety, Coherus Oncology, Inc. (CHRS) carries a lower debt/equity ratio of 2% versus 66% for MacroGenics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), MacroGenics, Inc.

(MGNX) is pulling ahead at 0. 8% versus -84. 2% for Coherus Oncology, Inc. (CHRS). On earnings-per-share growth, the picture is similar: Coherus Oncology, Inc. grew EPS 472. 0% year-over-year, compared to -10. 3% for MacroGenics, Inc.. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Coherus Oncology, Inc.

(CHRS) is the more profitable company, earning 398. 4% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 398. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MGNX leads at -48. 7% versus -22. 2% for FATE. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Arcus Biosciences, Inc.

(RCUS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Coherus Oncology, Inc. (CHRS) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RCUS: +49. 2%, CHRS: -90. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CHRS is a small-cap deep-value stock; MGNX is a small-cap quality compounder stock; RCUS is a small-cap quality compounder stock; FATE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.